On‐demand treatment with FFP was reported in 20.0% (16/80) symptomatic patients, C1‐INH in 13.8% (11/80), and icatibant in 8.8% (7/80). 17.5% (14/80) of symptomatic patients reported using other medications for the treatment of HAE attacks. The gene discussed is SERPING1; the disease is hereditary angioedema.